Group A streptococcus (GAS) diseases take 90% of streptococcal infection. GAS infection lead to over 111 million prevalent cases of streptococcal pyoderma, and 616 million new cases of GAS pharyngitis each year. Serious infections such as cellulitis,erysipelas, necrotic fasciitis, sepsis, ARF or PSGN can be resulted when the organism spreads to contiguous sites or disseminates to deep tissues.
There are nearly 150 serotypes of GAS, but there is no cross immunity among them. This property makes it particularly difficult to treat and prevent the GAS infections.Thus, a vaccine capable of preventing GAS infections from different serotypes becomes a good solution.
As for that GAS liposomal vaccine is a Class 1 new drug that has not been put into the market worldwidely, we guarantee that we will have abundant study data and reports to proven its safety and efficacy. Our clinical trial design standard will be far higher than the requirements on the clinical trials for new drugs of both China and Euro-american countries. Strict clinical trials’ management will make our data more reliable, and the safety and efficacy of the vaccine after its marketing can be ensured.